Emergo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:1
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 1
1 (25.0%)Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness
Phase 2
Completed
- Conditions
- InfluenzaInfluenza -Like Illness
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT04610047
- Locations
- 🇺🇸
Precision Trials AZ, Phoenix, Arizona, United States
🇺🇸Downtown LA Research Center, Los Angeles, California, United States
🇺🇸Omega Research Debary, DeBary, Florida, United States
Norketotifen for the Treatment of Uncomplicated Influenza-like Illness
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT04043923
- Locations
- 🇺🇸
Cahaba Research, Birmingham, Alabama, United States
🇺🇸Precision Trials AZ, Phoenix, Arizona, United States
🇺🇸Long Beach Clinical Trial Services, Long Beach, California, United States
Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis
Phase 2
Completed
- Conditions
- Allergic RhinitisAllergic Rhinoconjunctivitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03887026
- Locations
- 🇺🇸
Biogenics Research Chamber, San Antonio, Texas, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Norketotifen Oral Capsule (Cohort 3)Drug: Norketotifen Oral Capsule (Multiple Dose Cohort)Drug: Norketotifen Oral Capsule (Cohort 1)Drug: Norketotifen Oral Capsule (Cohort 2)Drug: Placebo Oral Capsule
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03712163
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
News
No news found